Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure

Abstract

Iron deficiency defined as depleted body iron stores and unmet cellular iron requirements is common in AHF, and identifies those with the poor outcome. Its correction may be an attractive therapeutic approach.

Iron deficiency: Prevalence and relation to cardiovascular biomarkers in heart failure outpatients

“…randomized studies evaluating the effect of oral or intravenous iron supplements on glycemic status in HF. We did not measure plasma concentrations of heptidin and soluble transferrin receptor and address this interesting part of the iron metabolism [15,16]. Finally, our data do support the ESC Guidelines for HF [17] which suggests that ID is frequent and should not be overlooked in HF outpatients and more knowledge on iron metabolism in HF is needed, e.g.…”

An essential cell-autonomous role for hepcidin in cardiac iron homeostasis

“…Indeed, systemic iron deficiency correlates with functional and molecular markers of disease severity in patients with chronic heart failure (CHF) (Klip et al, 2013; Comín-Colet et al, 2013),and also appears to contribute to the risk of death after an episode of acute heart failure (Jankowska et al, 2014). Given the high prevalence of iron deficiency in patients with CHF, ranging between 30–50% (Klip et al, 2013; Nanas et al, 2006; Ezekowitz et al, 2003), the European Society of Cardiology recently recommended the assessment of iron deficiency as a comorbidity in CHF.…”

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

“…W grupie chorych z HF niedobór żelaza wiąże się ze złym rokowaniem [467,468]. Dożylna suplementacja żelaza była przedmiotem dwóch RCT przeprowadzonych u chorych z HF i niedoborem żelaza (osoczowa ferrytyna < 100 µg/l lub ferrytyna 100-299 µg/l przy saturacji transferryny < 20%) [469,470], zarówno z niedokrwistością, jak i bez niedokrwistości.…”